Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 09 - 16 symbols : GILD save search
Trodelvy® Significantly Improved Quality of Life Over Standard of Care in 2L+ Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study
Published: 2021-09-16 (Crawled : 11:33) - biospace.com/
GILD | $66.665 -0.4% 1M
|
Health Technology
|
| O: 0.06%
H: 0.08%
C: -0.65%
cancer phase 3 breast cancer als
New Data Demonstrate Trodelvy® Survival Benefit in Metastatic Triple-Negative Breast Cancer Patients Regardless of Initial HR/HER2 Status
Published: 2021-09-16 (Crawled : 11:33) - biospace.com/
GILD | $66.665 -0.4% 1M
|
Health Technology
|
| O: 0.06%
H: 0.08%
C: -0.65%
cancer breast cancer her2+ her2- her2
Second Genome Presents Preclinical Data at ESMO 2021 Demonstrating that a Novel Microbiome-Derived Peptide, SG-3-00802, Reverses Resistance to Anti-Programmed Death Protein-1 (PD-1) Therapy
Published: 2021-09-16 (Crawled : 11:33) - biospace.com/
GILD | $66.665 -0.4% 1M
|
Health Technology
|
| O: 0.06%
H: 0.08%
C: -0.65%
therapy preclinical pre-clinical
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
TIRX | $1.13 133.09% 44M
|
AGBA | $0.8978 124.45% 60M
|
Finance
BPTH | $6.18 90.74% 39M
|
Health Technology
INVO | $1.44 89.47% 3M
|
Health Technology
XPON | $2.66 37.82% 5.2M
|
SINT | $0.0504 35.12% 300M
|
Health Technology
THCH | $1.38 32.69% 9.9M
|
n/a
ALRN | $5.605 31.88% 210K
|
Health Technology
HOLO | $2.92 30.36% 22M
|
VTNR S | $1.25 27.66% 3.2M
|
Industrial Services
Your saved searches
Save your searches and get alerts when important news are released.